- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: Trilaciclib (G1T28) is an investigational short-acting CDK4/6 inhibitor being developed by G1 Therapeutics .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC. (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.
Mol. Cancer Ther., 15 (5): 783-93. [PMID:26826116]
2. He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ et al.. (2017)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.
Sci Transl Med, 9 (387). [PMID:28446688]